» Articles » PMID: 30285501

The Usefulness of Listening Social Media for Pharmacovigilance Purposes: a Systematic Review

Overview
Specialty Pharmacology
Date 2018 Oct 5
PMID 30285501
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Social media mining could be a possible strategy to retrieve drug safety information. The mining of social media is a complex process under progressive evolution, falling into three broad categories: listening (safety data reporting), engaging (follow-up), and broadcasting (risk communication). This systematic review is aimed at evaluating the usefulness and quality of proto-signals by social media listening. Areas covered: In this systematic search, performed according to MOOSE and PRISMA statements, we selected studies, published in MEDLINE, EMBASE, and Google Scholar until 31 December 2017, that listened at least one social media to identify proto-adverse drug events and proto-signals. Expert opinion: The selected 38 studies identified serious and unexpected proto-adverse drug events characterized by poorer information quality as compared with spontaneous reporting databases. This feature allows rarely the evaluation of causal relationships. Proto-signals identified by social media listening had the potential of anticipating pre-specified known signals in only six studies. Moreover, the personal perception of patients reported in social media could be used to implement effective risk communication strategies. However, signal detection in social media cannot be currently recommended for routine pharmacovigilance, due to logistic and technical issues.

Citing Articles

One size fits all: Enhanced zero-shot text classification for patient listening on social media.

Matoshi V, De Vuono M, Gaspari R, Kroll M, Jantscher M, Nicolardi S Front Artif Intell. 2025; 7:1397470.

PMID: 40007771 PMC: 11850375. DOI: 10.3389/frai.2024.1397470.


Pharmacovigilance in the Age of Legalized Cannabis: Using Social Media to Monitor Drug-Drug Interactions Between Immunosuppressants and Cannabis-Derived Products.

Allen M, Wightman G, Zhu Z, Poliak A, Smith D, Dredze M Drug Saf. 2024; 48(1):99-105.

PMID: 39292423 DOI: 10.1007/s40264-024-01481-x.


The Value of Social Media Analysis for Adverse Events Detection and Pharmacovigilance: Scoping Review.

Golder S, OConnor K, Wang Y, Klein A, Hernandez G JMIR Public Health Surveill. 2024; 10:e59167.

PMID: 39240684 PMC: 11415724. DOI: 10.2196/59167.


Leveraging patient experience data to guide medicines development, regulation, access decisions and clinical care in the EU.

Almeida D, Umuhire D, Gonzalez-Quevedo R, Antonio A, Burgos J, Verpillat P Front Med (Lausanne). 2024; 11:1408636.

PMID: 38846141 PMC: 11153762. DOI: 10.3389/fmed.2024.1408636.


Patient listening on social media for patient-focused drug development: a synthesis of considerations from patients, industry and regulators.

Cimiano P, Collins B, De Vuono M, Escudier T, Gottowik J, Hartung M Front Med (Lausanne). 2024; 11:1274688.

PMID: 38515987 PMC: 10955474. DOI: 10.3389/fmed.2024.1274688.